EnteroBiotix's James McIlroy says EBX-102-02 could address treatment gaps in IBS, which impacts up to 10% of the global population.

Here are three high-impact areas where therapy providers could consider deploying AI to maximize their return on investment.

Pelvic floor PT is more sophisticated and effective than Instagram makes it seem.

Predicting the outcome of mental health therapy is a vital goal. Statistical models have been used. Now, we turn to using AI ...

The study, titled "Applications of Artificial Intelligence (AI) in Breast Cancer Care Delivery and Education: A Scoping ...

Teva will pay $700 million upfront plus $200 million in commercial milestones, along with royalties on global net sales, with ...

She reminds him, if he lies to her, Xander is breaking the conditions of his therapy (Again, not cool, Doctor Evans). Xander ...

Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with ...

When an adult patient develops sepsis, clinicians often prescribe corticosteroids to counteract the dysregulated immune ...

Q4 2025 Earnings Call April 28, 2026 8:00 AM EDTCompany ParticipantsJan Keppeler - Head of Investor Relations, Sustainability ...

Ecopipam, Emalex's investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The late- ...